National measles guidelines
How to manage cases of suspected measles: what patient details to take, who to notify and assessing risk of disease spreading in close contacts.
Applies to England
Documents
Details
The national measles guidelines for health professionals covers:
- how to decide if a suspected case of measles is ‘likely’ or ‘unlikely’
- case management – what lab tests should be done and the importance of oral fluid testing on all suspected cases
- measles control – identifying vulnerable contacts and assessing their need for post-exposure prophylaxis
As detailed in the guidance, the measles warn and inform letter can be used where it is necessary to contact a number of people who have been potentially exposed to a case of measles – please see the guidelines for further information about this.
The measles factsheet can be given to individuals to give them information about:
- what measles is and how it spreads
- symptoms and complications of measles
- vaccination
- what to do if you have measles
Translations of warn and inform letters
These translated warn and inform letters open as Word documents.
- Albanian
- Amharic
- Arabic
- Bengali
- Cantonese
- Dari
- Farsi
- French
- Gujarati
- Hindi
- Italian
- Lithuanian
- Mandarin
- Nepali
- Pahari Pothwari
- Pashto
- Polish
- Portuguese
- Punjabi Shahmukhi
- Punjabi Gurmukhi
- Romanian
- Shona
- Slovak
- Somali
- Spanish
- Sylheti
- Tagalog
- Tamil
- Tigrinya
- Turkish
- Ukrainian
- Urdu
Translations of easy read warn and inform letters
These translated easy read warn and inform letters open as PDF documents.
- Arabic
- Bengali
- Dari
- Farsi
- Gujarati
- Mandarin
- Pashto
- Polish
- Portuguese
- Punjabi
- Romanian
- Somali
- Spanish
- Urdu
Translations of factsheets
These translated factsheets open as PDF documents.
Updates to this page
Last updated 25 July 2024 + show all updates
-
Guidance updated - see page 3 for change history.
-
Added the translated easy read warn and inform letters.
-
Added measles easy ready factsheet.
-
Updated National measles guidelines - see page 3 for change history.
-
Added the easy read warn and inform letter.
-
Added translations of the warn and inform letters and factsheets.
-
Clarification of responsibilities for risk assessment in healthcare settings page 37. Further product information added on immunoglobulin product, Cuvitru, page 35.
-
Added factsheet and updated letter.
-
Updated guidance see page 3 for change history.
-
Updated guidance, including additional section on defining the time window for receiving post-exposure prophylaxis (PEP).
-
Updated guidance.
-
Added latest version of guidelines.
-
Updated to reflect revised clinical advice.
-
First published.